Latest News from: Intellia Therapeutics

Filters close
Released: 11-Nov-2020 9:30 AM EST
Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis
 Intellia Therapeutics

Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis

Comment
11-Nov-2020 7:30 AM EST
Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments
 Intellia Therapeutics

Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments

Comment
   

Showing results 1 – 2 of 2


close
0.2106